Hemophilia B: all 275 studies

Page 1 of 3. Open to participants first (52), then studies with results posted, then the rest; newest registration first within each.

• A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With HemophiliaNot yet recruitingNCT07876674Phase 3
• Multicomponent Pain Self-Management in Adults With Haemophilic ArthropathyNot yet recruitingNCT07860632Not applicable
• A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or BNot yet recruitingNCT07859527
• Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy PeersNot yet recruitingNCT07736976
• CD19-B Cell Depletion in PAIS-ME/CFS PatientsNot yet recruitingNCT07724834Phase 2
• Ultrasound Assessment of Joint Health in Patients With Mild Hemophilia (Factor Levels 5-40%)Not yet recruitingNCT07719647Not applicable
• Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)Not yet recruitingNCT07714213Phase 2
• Effects of Dexmedetomidine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic ShockNot yet recruitingNCT07657715Not applicable
• Effects of Anisodamine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic ShockNot yet recruitingNCT07657702Not applicable
• An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyRecruitingNCT07644832Phase 1/2
• Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BRecruitingNCT07080905Phase 3
• Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With AlhemoEnrolling by invitationNCT06831734
• ATHNdataset RegistryRecruitingNCT06820515
• Synovial Proliferation on Routine Ultrasound: Active or Inactive?RecruitingNCT06809972
• KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without InhibitorsNot yet recruitingNCT06747416Phase 2
• Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669
• An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia BRecruitingNCT06700096Phase 3
• Measurement Properties in People with HemophiliaRecruitingNCT06565481Not applicable
• A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia BRecruitingNCT06379789Phase 1/2
• A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)RecruitingNCT06349473Phase 1
• Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With InhibitorsEnrolling by invitationNCT06285071
• Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)RecruitingNCT06158334
• Development of Non-Invasive Prenatal Diagnosis for Single Gene DisordersRecruitingNCT06147414
• Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac SurgeryRecruitingNCT06144125Phase 4
• Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001Not yet recruitingNCT06125756Early Phase 1
• Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)RecruitingNCT06120582Phase 1/2
• Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001Not yet recruitingNCT06119659Early Phase 1
• Alterations in Coagulation Factor Levels in Patients With End Stage Liver DiseaseNot yet recruitingNCT06014320
• An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BRecruitingNCT06008938
• Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)RecruitingNCT06003387Phase 3
• Viscoelastic Properties of Lower Extremity Muscles in Patients With HemophiliaNot yet recruitingNCT05981313
• Patterns of Hemophilia Care in Assiut Children PatientsNot yet recruitingNCT05980377
• Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)Enrolling by invitationNCT05962398
• Liver Biopsy Following Gene Therapy For HemophiliaNot yet recruitingNCT05932914
• Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldRecruitingNCT05709288Phase 1
• A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B PatientsRecruitingNCT05641610Phase 1/2
• The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.RecruitingNCT05630651Not applicable
• A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Phase 3
• Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B RespectivelyRecruitingNCT05568719Phase 3
• Safety and Tolerability of VGB-R04 in Patients With Haemophilia BRecruitingNCT05152732Early Phase 1
• Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Phase 3
• Liver Biopsy In Haemophilia Gene TherapyRecruitingNCT04817462Not applicable
• SEVENFACT® for Bleeding Events in Hemophilia With InhibitorsRecruitingNCT04647227Phase 4
• National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
• SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisRecruitingNCT04563520Phase 3
• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersRecruitingNCT04398628
• Lentiviral FIX Gene TherapyNot yet recruitingNCT03961243Phase 1
• A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYNEnrolling by invitationNCT03745924
• Adverse Event Data Collection From External Registries on Nonacog Beta PegolEnrolling by invitationNCT03690336
• World Bleeding Disorders RegistryRecruitingNCT03327779
• The European Paediatric Network for Haemophilia Management ( PedNet Registry)RecruitingNCT02979119
• German Pediatric Hemophilia Research DatabaseRecruitingNCT02912143
• An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog AlfaTerminatedNCT05856266Phase 4Results posted
• A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia BCompletedNCT05365217Phase 3Results posted
• Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia BTerminatedNCT05164471Phase 1/2Results posted
• A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B SubjectsTerminatedNCT04394286Phase 1/2Results posted
• Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia BCompletedNCT04286412Phase 4Results posted
• Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac SurgeryTerminatedNCT04244981Phase 4Results posted
• Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With HemophiliaCompletedNCT04072237Phase 1Results posted
• Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia BCompletedNCT03995784Phase 2Results posted
• Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BCompletedNCT03938792Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia BActive, not recruitingNCT03861273Phase 3Results posted
• Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia BCompletedNCT03855280Phase 3Results posted
• A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)CompletedNCT03587116Phase 3Results posted
• HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B PatientsCompletedNCT03569891Phase 3Results posted
• RIXUBIS PMS India (RIXUBIS PMS)CompletedNCT03565237Phase 4Results posted
• Dose Confirmation Trial of AAV5-hFIXco-PaduaCompletedNCT03489291Phase 2Results posted
• A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsCompletedNCT03417245Phase 3Results posted
• A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsCompletedNCT03417102Phase 3Results posted
• Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and BCompletedNCT03407651Phase 2Results posted
• A Factor IX Gene Therapy Study (FIX-GT)TerminatedNCT03369444Phase 1/2Results posted
• Understanding Hemophilia A and B Drug Dosage Administration PatternsTerminatedNCT03248141Results posted
• A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With InhibitorsCompletedNCT03196284Phase 2Results posted
• Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B PatientsCompletedNCT03186677Phase 1Results posted
• Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia BCompletedNCT03091751Phase 2Results posted
• RIXUBIS Drug Use-Result Survey (Japan)CompletedNCT02937831Results posted
• Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort StudyCompletedNCT02740413Results posted
• Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia BTerminatedNCT02695160Phase 1Results posted
• Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia BTerminatedNCT02618915Phase 1/2Results posted
• An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or BCompletedNCT02554773Phase 1/2Results posted
• Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 TrialCompletedNCT02541942Phase 2Results posted
• A Gene Therapy Study for Hemophilia BCompletedNCT02484092Phase 2Results posted
• A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIaCompletedNCT02448680Phase 3Results posted
• Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia BCompletedNCT02396342Phase 1/2Results posted
• Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in ChinaCompletedNCT02336178Phase 4Results posted
• Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia BCompletedNCT02234310Phase 3Results posted
• An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia BCompletedNCT02213250Phase 1Results posted
• An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With HemophiliaCompletedNCT02199717Results posted
• Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia BCompletedNCT02141074Phase 3Results posted
• A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia BCompletedNCT02053792Phase 3Results posted
• Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With InhibitorsCompletedNCT02020369Phase 3Results posted
• Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand RegimenCompletedNCT01757405Phase 3Results posted
• A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia BCompletedNCT01662531Phase 3Results posted
• BAX 326 Surgery Study in Hemophilia B PatientsCompletedNCT01507896Phase 3Results posted
• A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia BCompletedNCT01496274Phase 2/3Results posted
• BAX 326 Pediatric StudyCompletedNCT01488994Phase 2/3Results posted
• Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.CompletedNCT01467427Phase 3Results posted
• Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia BCompletedNCT01440946Phase 3Results posted
• Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia BCompletedNCT01425723Phase 3Results posted
• Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773CompletedNCT01395810Phase 3Results posted

← Hemophilia B overview